Lawrence Karsh, MD, FACS
No bio available.
Financial relationships
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:Veru PharmaceuticalsMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:NeoGenomic LaboratoriesMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:EMD SeronoMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:MinomicMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:NucleixMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:SiemansMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (Oncology)Ineligible company:CepheidMitigation strategy:DivestDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:Arivan ResearchMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:PfizerMitigation strategy:Peer reviewDate reviewed:09/20/2022
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:MyovantMitigation strategy:Peer reviewDate reviewed:09/20/2022